1-8 of 8
Wayne Rothbaum
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel
Journal: Blood
Blood (2024) 144 (Supplement 1): 1808.2.
https://doi.org/10.1182/blood-2024-200966
Published: 2024
Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 1000.
https://doi.org/10.1182/blood-2024-201642
Published: 2024
Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi
Journal: Blood
Blood (2024) 144 (Supplement 1): 483.
https://doi.org/10.1182/blood-2024-205937
Published: 2024
Journal Articles

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Paulina Marie Budde, Helal Ahmed, Todd Covey, Cecile Krejsa, Wayne Rothbaum, Nikolas Von Bubnoff, Cyrus Khandanpour
Journal: Blood
Blood (2023) 142 (Supplement 1): 2782.
https://doi.org/10.1182/blood-2023-174895
Published: 2023
Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

John C. Byrd, Dariusz Woszczyk, Arpad Illes, Wojciech Jurczak, Dominik Chraniuk, Krzysztof Giannopoulos, Nataliia Mikhailova, Peter Illconzai, Seema A Bhat, Nataliya Romanyuk, Ganna Usenko, Olha Kuchkova, Jason Chandler, Elizabeth Bilotti, Annalise Shen, Jean Cheung, Srdan Verstovsek, Jesse McGreivy, Wayne Rothbaum, Maciej Kaźmierczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4634.
https://doi.org/10.1182/blood-2023-186517
Published: 2023
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

John C. Byrd, MD, William Wierda, MD PhD, Jeffrey Jones, MD MPH, Susan O'Brien, MD, Jennifer R. Brown, MD PhD, Anna Schuh, MD PhD, Peter Hillmen, MB, ChB, PhD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Steve Devereux, MD, Jorge M. Chaves, MD, Jacqueline C. Barrientos, MD, Min Hui Wang, PhD, Jane Huang, MD, Todd Covey, Tasheda Navarro, Wayne Rothbaum, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Richard R. Furman, MD
Journal: Blood
Blood (2015) 126 (23): 831.
https://doi.org/10.1182/blood.V126.23.831.831
Published: 2015